U.S. Preventive Services Task Force
Aspirin for the Primary Prevention of Cardiovascular Events - Chemoprevention
Release Date: January 2002
Summary of Recommendations / Supporting Documents
Summary of Recommendations
- The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for coronary heart disease (CHD) (go to Clinical Considerations). Discussions with patients should address both the potential benefits and harms of aspirin therapy.
Rating: A recommendation.
Rationale: The USPSTF found good evidence that aspirin decreases the incidence of coronary heart disease in adults who are at increased risk for heart disease. They also found good evidence that aspirin increases the incidence of gastrointestinal bleeding and fair evidence that aspirin increases the incidence of hemorrhagic strokes. The USPSTF concluded that the balance of benefits and harms is most favorable in patients at high risk of CHD (5-year risk of greater than or equal to 3 percent) but is also influenced by patient preferences.
Top of Page
Supporting Documents
Aspirin for the Primary Prevention of Cardiovascular Events, January 2002
Recommendations and Rationale (PDF File, 72 KB)
Summary of the Evidence (PDF File, 114 KB)
What's New
Press Release
Audio News Release
-->
Top of Page
Return to USPSTF Topic Index
Return to Category Listing
Return to USPSTF Home Page